By Josh White
Date: Monday 23 Sep 2024
(Sharecast News) - Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic advancements in its interim results on Monday.
Holding(s) in Company | 29-Apr-2025 | 18:14 | RNS |
2025 Annual General Meeting notification | 28-Apr-2025 | 13:00 | RNS |
Holding(s) in Company | 23-Apr-2025 | 17:45 | RNS |
Preliminary results for the year ended 31 Dec 2024 | 09-Apr-2025 | 07:00 | RNS |
Holding(s) in Company | 04-Apr-2025 | 08:52 | RNS |
Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
Need to know | 10-May-2008 | Times |
DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
Oxford Biomedica seals €518m deal with Sanofi ov... | 29-Mar-2007 | Times |
No recent information was found.
Currency | UK Pounds |
Share Price | 285.50p |
Change Today | -12.00p |
% Change | -4.03 % |
52 Week High | 445.00 |
52 Week Low | 232.50 |
Volume | 77,489 |
Shares Issued | 106.00m |
Market Cap | £302.62m |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 9 |
No dividends found |
Time | Volume / Share Price |
15:11 | 169 @ 286.49p |
15:02 | 560 @ 285.50p |
15:02 | 211 @ 285.50p |
15:00 | 17 @ 285.00p |
15:00 | 100 @ 284.50p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research